Qubit Pharmaceuticals
Qubit Pharmaceuticals is a Paris-based Deep Tech company building quantum-AI molecular modeling tools, including the ATLAS platform and FeNNix-Bio1 foundation model, to accelerate drug discovery. It partners with pharmaceutical companies, biotechs and academic institutions on co-developed drug programs in oncology, inflammation and antivirals.
- Company typePrivate
- Founded2020
- HeadquartersParis, France
- Headcount51–100
- GTM typeB2B
- OfferingSoftware
What Qubit Pharmaceuticals does
Qubit Pharmaceuticals is a Paris-headquartered Deep Tech company, founded in 2020, that applies quantum computing, physics-based simulation and artificial intelligence to accelerate drug discovery for targets previously considered undruggable. Its proprietary ATLAS platform combines 50+ PetaFLOPS of NVIDIA DGX AI compute, 1000+ nanoseconds per day of polarizable molecular dynamics simulation, and hybrid HPC–quantum computing readiness over 30 qubits to deliver high-precision molecular modeling and molecule generation. In May 2025 the company extended this stack with FeNNix-Bio1, a quantum-enabled foundation model for biomolecular systems co-developed with Sorbonne University that is positioned as the first AI model capable of simulating chemical reactivity at quantum-level accuracy and scale.
The company operates a B2B partnership-based business model, monetising through joint drug discovery programs, in-licensing/out-licensing opportunities, and co-development deals that combine professional services with potential milestone payments and royalties. Customer segments are pharmaceutical and biotechnology companies seeking pipeline acceleration, alongside academic and research institutions used for technology co-development and biological validation (e.g., Institut Curie for TREX1 cancer immunotherapy, University of Bordeaux, Centre for Quantum Technologies Singapore, Argonne National Laboratory). Go-to-market is direct enterprise engagement; pricing is bespoke and not publicly disclosed.
Qubit runs an internal and partnered pipeline of six drug discovery programs — targeting KAT6A, RAS/RAF, TREX1 (STING pathway), IL4R, USP7 and MRas — plus 16 additional discovery programs in oncology, inflammation and antivirals, including an RNA therapeutics platform. The team of 60+ employees includes 30+ PhDs across offices in Paris, Boston and Chicago, and is led by five co-founders heading quantum chemistry laboratories at Sorbonne University, Washington University in St. Louis and the University of Texas at Austin. The company has raised $25M+ from Xange, Omnes, Quantonation, Octave Klaba and the European Innovation Council, and was named a World Economic Forum Technology Pioneer in 2024.
Qubit Pharmaceuticals firmographics
Firmographics- Name
- Qubit Pharmaceuticals
- Legal name
- QUBIT PHARMACEUTICALS
- Website
- https://qubit-pharmaceuticals.com
- Company type
- Private
- Founded year
- 2020
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Qubit Pharmaceuticals is a Paris-based Deep Tech company building quantum-AI molecular modeling tools, including the ATLAS platform and FeNNix-Bio1 foundation model, to accelerate drug discovery. It partners with pharmaceutical companies, biotechs and academic institutions on co-developed drug programs in oncology, inflammation and antivirals.
- Ownership category
- akta.pro rank
Qubit Pharmaceuticals industry classification
Industry- Product category
- Computational Drug Discovery Software
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836), Laboratory Analytical Instruments (3826)
- akta.pro primary industry
- AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE)
- akta.pro secondary industries
- AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO), Pharmaceutical & Biotech R&D Simulation (drug discovery, protein/ligand) (HDAGAEAB), Protein Interaction & Structural Biology Platforms (cryo-EM, X-ray, NMR, biophysics) (HLAAAIAH)
Keywords
Where Qubit Pharmaceuticals is headquartered
LocationHeadquarters
- HQ city
- Paris
- HQ country
- France
- HQ region
- Europe
Offices3 records
Markets served
Qubit Pharmaceuticals business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Infrastructure, Marketing or Sales, Operations
Revenue model
- Joint Drug Discovery Programs: Co-development partnerships with pharmaceutical and biotech companies where Qubit provides computational drug discovery services using its Atlas platform, with costs and outcomes shared between parties.
- Licensing and Co-development Deals: Revenue from licensing its technology platform and co-developing drug candidates with partners, with potential milestone payments and royalties on successful drug development.
Go-to-market motion2 records
Distribution channels1 record
Marketing channels7 records
Qubit Pharmaceuticals product offering
Product offeringCore offering
Qubit Pharmaceuticals develops and operates ATLAS, a proprietary computational platform combining quantum computing, artificial intelligence, and physics-based molecular modeling to accelerate drug discovery. The platform enables high-precision molecular simulation, molecule generation, and lead optimization for pharmaceutical and biotech partners through joint drug discovery programs, co-development, and licensing arrangements. It also operates an internal pipeline of drug discovery programs in oncology, inflammation, antivirals, and RNA therapeutics.
Product overview
Qubit Pharmaceuticals offers a unified platform architecture centered on the ATLAS platform, a proprietary quantum AI and physics-inspired system for high-precision molecular modeling in drug discovery. ATLAS is enhanced by FeNNix-Bio1, a quantum AI foundation model that extends the platform's capabilities to provide quantum-level accuracy for molecular simulations at scale. The company operates a pipeline of drug discovery programs in oncology, inflammation, and antivirals, including programs targeting KAT6A, RAS/RAF, TREX1, STING pathway, and RNA platforms. The technology stack combines high-performance computing (50+ PetaFLOPS AI), quantum computing capabilities (30+ qubits), and molecular dynamics simulation (1000+ nanoseconds per day) to enable drug discovery workflows from target characterization through lead optimization.
Differentiator
Problem solved
Functional benefit
Products and services
- ATLAS Platform Proprietary quantum, AI and physics-inspired computational platform for high-precision molecular modeling and drug discovery, offered to pharmaceutical and biotech partners through joint drug discovery programs, in-licensing, out-licensing, and co-development arrangements.
- FeNNix-Bio1 Quantum AI Foundation Model Quantum AI foundation model for biomolecular simulations that delivers quantum-level accuracy at speeds rivalling traditional force field methods, enabling simulation of molecular reactivity, protein dynamics, and drug-protein interactions at unprecedented scale.
Quantifiable outcome
- Reduces drug candidate selection and optimization time by 50%
- +6 more outcomes
Companies that use Qubit Pharmaceuticals
Customer profileNamed customers3 records
Segments3 records
Ideal customer profiles3 records
Qubit Pharmaceuticals technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability6 records
Feature8 records
Qubit Pharmaceuticals partnerships and signals
Strategic signalPartnerships
Nine partnerships are on record, tiered core, major and minor.
- Centre for Quantum Technologies (CQT)coreTwo-year strategic research collaboration to develop and implement novel quantum algorithms for molecular discovery. Implementing variational quantum eigensolvers, quantum phase estimation, and qMCMC algorithms on Quantinuum H2 and Helios quantum hardware. First successful implementation of qMCMC algorithm on physical quantum hardware.
- Sorbonne UniversitycoreJoint development of FeNNix-Bio1 quantum AI model for drug discovery. Partnership leverages unprecedented computing power from GENCI, EuroHPC and Argonne National Laboratory to create world's most accurate synthetic molecular database.
- Argonne National LaboratorymajorAwarded 1.44 million GPU hours through INCITE Program for access to Aurora exascale supercomputer for molecular simulation research
- PasqalcoreJoint research on analog quantum computing for drug discovery, specifically for solvent configuration prediction in protein structures. Demonstrated algorithm with 14 qubits in practical drug design context.
- Unitary FundminorJoint winner of Wellcome Trust's Quantum for Bio program alongside Pasqal for quantum computing applications in biology
- Acuité Québec ConsortiumminorJoined consortium to innovate in drug design using quantum computing resources in Quebec
- Université de SherbrookemajorPartnership with Institute of Pharmacology at University of Sherbrooke, Canada for drug discovery research
- Institut CuriecoreCollaboration to develop drug candidates targeting TREX1 enzyme for cancer immunotherapy. Qubit provides computational modeling via Atlas platform, Institut Curie provides biological validation through their Cancer Immunotherapy Center.
- University of BordeauxmajorResearch partnership for biochemical and structural characterization of identified drug leads in cancer therapy development. Working with CNRS researchers specialized in molecular interactions.
Scale indicators9 records
Recent moves6 records
Expansion highlights6 records
Qubit Pharmaceuticals competitors and assessment
Company assessmentDirect peers
- Schrödinger Inc. Schrödinger is the publicly listed leader in physics-based computational drug discovery, offering platforms (LiveDesign, Maestro) for molecular simulation and FEP+ for binding free energy. Directly comparable to Qubit's ATLAS platform; notably, Qubit's new CTO Robin Chaudret was previously an Executive Director at Schrödinger.
- XtalPi: XtalPi combines AI, quantum physics, and large-scale HPC for small-molecule drug discovery and has raised over $700M. It is the most direct peer to Qubit, with a near-identical quantum-plus-AI positioning and pharma partnership model.
- Recursion Pharmaceuticals: Recursion is an AI-driven drug discovery company combining high-throughput biology with deep learning. Comparable as an AI-native drug discovery platform pursuing both internal pipeline and pharma partnerships; differentiated from Qubit by its wet-lab emphasis versus Qubit's in silico/quantum focus.
- Insilico Medicine: Insilico Medicine uses generative AI for target identification and molecule generation, with a pipeline that has reached clinical stage. Comparable to Qubit as an AI-first drug discovery company pursuing pharma partnerships and internal pipeline development.
- Isomorphic Labs: Isomorphic Labs is Alphabet's drug discovery spin-out leveraging DeepMind's AlphaFold technology. Directly comparable to Qubit as a foundation-model-driven drug discovery company pursuing major pharma partnerships (Novartis, Lilly).
- Atomwise: Atomwise applies AI (AtomNet) to small-molecule drug discovery and has partnered with multiple large pharma companies. Comparable as an AI-first drug discovery platform pursuing a similar partnership-driven GTM.
Emerging players
- Iambic Therapeutics: Iambic (formerly Entasis) uses AI/ML for small-molecule drug discovery with a foundation-model approach (Enchant and NeuralPLexer). Comparable in early-stage AI drug discovery with similar pipeline ambition.
- Polaris Quantum Biotech: Polaris Quantum Biotech applies quantum computing to drug design, with a narrower focus on oncology targets. Comparable to Qubit as a quantum-focused drug discovery peer, though smaller in scale and pipeline breadth.
- Menten AI: Menten AI develops AI-designed protein therapeutics and de novo enzymes. Comparable as an AI-first biotech platform with quantum/ML underpinnings, overlapping with Qubit's protein engineering use cases.
Others
- Pasqal: Pasqal is a neutral-atom quantum computing hardware company and an active collaborator with Qubit on analog quantum algorithms for solvent configuration. Comparable as an ecosystem enabler supplying the underlying quantum compute that powers Qubit's platform rather than as a direct drug discovery competitor.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Qubit Pharmaceuticals social profiles
Digital presenceQubit Pharmaceuticals financial estimates
Financial estimateRevenue estimate
Valuation estimate
Qubit Pharmaceuticals leadership team
Management profileNumber of profiles
Profiles8 records
Qubit Pharmaceuticals funding detail
Funding detailFunding overview
Funding rounds2 records
Investors4 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Qubit Pharmaceuticals M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Qubit Pharmaceuticals
What does Qubit Pharmaceuticals do?
Qubit Pharmaceuticals develops and operates ATLAS, a proprietary computational platform combining quantum computing, artificial intelligence, and physics-based molecular modeling to accelerate drug discovery. The platform enables high-precision molecular simulation, molecule generation, and lead optimization for pharmaceutical and biotech partners through joint drug discovery programs, co-development, and licensing arrangements. It also operates an internal pipeline of drug discovery programs in oncology, inflammation, antivirals, and RNA therapeutics.
Is Qubit Pharmaceuticals a public or private company?
Qubit Pharmaceuticals is a private company. It is classified as venture growth investor backed and is currently operating.
When was Qubit Pharmaceuticals founded?
Qubit Pharmaceuticals was founded in 2020. It employs 51 to 100 people.
Where is Qubit Pharmaceuticals based?
Qubit Pharmaceuticals is headquartered in Paris, France, in the Europe region.
How does Qubit Pharmaceuticals make money?
Two revenue lines are on record. Joint Drug Discovery Programs are the primary driver. The others are licensing and Co-development Deals.
Who are Qubit Pharmaceuticals's main competitors?
Direct peers on record are Schrödinger Inc., XtalPi, Recursion Pharmaceuticals, Insilico Medicine, Isomorphic Labs and Atomwise. Emerging players are Iambic Therapeutics, Polaris Quantum Biotech and Menten AI. Pasqal is listed as an others.
Does Qubit Pharmaceuticals have an API?
No public API is recorded for Qubit Pharmaceuticals.
What industry is Qubit Pharmaceuticals in?
Qubit Pharmaceuticals's product category is Computational Drug Discovery Software. Its primary akta.pro industry code is HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening), with a secondary code of HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization. Its NAICS code is 541714 and its SIC code is 2834.